Should I buy or sell TELA Bio stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TELA Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TELA shares. View TELA analyst ratings or view top-rated stocks .

What is TELA Bio's stock price target for 2024?

3 equities research analysts have issued 12 month price objectives for TELA Bio's stock. Their TELA share price targets range from $12.00 to $15.00. On average, they predict the company's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 165.4% from the stock's current price. View analysts price targets for TELA or view top-rated stocks among Wall Street analysts .

How have TELA shares performed in 2024?

TELA Bio's stock was trading at $6.62 at the start of the year. Since then, TELA stock has decreased by 22.2% and is now trading at $5.15. View the best growth stocks for 2024 here .

When is TELA Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TELA earnings forecast .

How were TELA Bio's earnings last quarter?

TELA Bio, Inc. (NASDAQ:TELA) released its earnings results on Thursday, March, 21st. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.09. The business had revenue of $17 million for the quarter, compared to analyst estimates of $16.65 million. TELA Bio had a negative trailing twelve-month return on equity of 201.62% and a negative net margin of 79.83%.

What ETF holds TELA Bio's stock?

Jacob Forward ETF holds 23,758 shares of TELA stock, representing 3.71% of its portfolio.

What guidance has TELA Bio issued on next quarter's earnings?

TELA Bio updated its FY 2024 earnings guidance on Thursday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $74.0 million-$76.0 million, compared to the consensus revenue estimate of $75.2 million.

What other stocks do shareholders of TELA Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TELA Bio investors own include Micron Technology (MU) , Intel (INTC) , Pfizer (PFE) , CrowdStrike (CRWD) , Walt Disney (DIS) , Gilead Sciences (GILD) , Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Alteryx (AYX) and Cisco Systems (CSCO) .

When did TELA Bio IPO?

TELA Bio (TELA) raised $60 million in an IPO on Friday, November 8th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

How do I buy shares of TELA Bio?

Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TELA

TELA Bio (TELA) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free TELA Stock Alerts

$5.15

-0.02 (-0.39%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.97
▼
$5.17
50-Day Range: $4.70
▼
$7.46
52-Week Range: $4.23
▼
$11.26

Volume: 95,186 shs
Average Volume: 135,540 shs
Market Capitalization: $126.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Get TELA Bio alerts:

TELA Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 165.4% Upside
$13.67 Price Target
Short Interest: Bearish
3.19% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.23
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.61) to ($1.05) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.66 out of 5 stars

Medical Sector

632nd out of 918 stocks

Surgical & Medical Instruments Industry

64th out of 91 stocks

3.5

Analyst's Opinion

Consensus Rating
TELA Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
TELA Bio has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.19% of the outstanding shares of TELA Bio have been sold short.
Short Interest Ratio / Days to Cover
TELA Bio has a short interest ratio ("days to cover") of 7.
Change versus previous month
Short interest in TELA Bio has recently increased by 9.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
TELA Bio does not currently pay a dividend.
Dividend Growth
TELA Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TELA.

1.8

News and Social Media Coverage

News Sentiment
TELA Bio has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for TELA Bio this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for TELA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TELA Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.70% of the stock of TELA Bio is held by insiders.
Percentage Held by Institutions
94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for TELA Bio are expected to grow in the coming year, from ($1.61) to ($1.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TELA Bio is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TELA Bio is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TELA Bio has a P/B Ratio of 6.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About TELA Bio Stock (NASDAQ:TELA)

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TELA Stock News Headlines

April 17, 2024 | msn.com

TELA Bio Launches Innovative Hernia Repair Device in the U.S. Market

April 16, 2024 | msn.com

TELA Bio launches OviTex IHR for inguinal hernia repair in US

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 15, 2024 | globenewswire.com

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

April 11, 2024 | finance.yahoo.com

MDXG: Legal Avenues

April 10, 2024 | msn.com

TELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical Affairs

April 8, 2024 | finanznachrichten.de

TELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

April 8, 2024 | globenewswire.com

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 25, 2024 | msn.com

TELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024

March 24, 2024 | finance.yahoo.com

Analysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year Results

March 23, 2024 | seekingalpha.com

TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript

March 23, 2024 | finance.yahoo.com

TELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)

March 22, 2024 | stockhouse.com

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

March 22, 2024 | finance.yahoo.com

TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcript

March 22, 2024 | finance.yahoo.com

Q4 2023 TELA Bio Inc Earnings Call

March 21, 2024 | benzinga.com

Recap: TELA Bio Q4 Earnings

March 21, 2024 | msn.com

TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023

March 21, 2024 | finance.yahoo.com

TELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023

March 21, 2024 | markets.businessinsider.com

Strategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA Bio

March 21, 2024 | finance.yahoo.com

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

March 21, 2024 | globenewswire.com

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

March 21, 2024 | markets.businessinsider.com

Tela Bio Announces Commercial Launch Of Liquifix Devices In U.S.

March 21, 2024 | globenewswire.com

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

March 20, 2024 | marketwatch.com

TELA Bio Sells Distribution Rights to Wound-Care Product to Mimedx

March 20, 2024 | markets.businessinsider.com

TELA Bio is about to announce its earnings — here's what to expect

March 20, 2024 | globenewswire.com

TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX

See More Headlines

Receive TELA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:TELA
CUSIP: N/A
CIK: 1561921
Web: www.telabio.com
Phone: 484-320-2930
Fax: N/A
Employees: 227
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.67
High Stock Price Target: $15.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +165.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,660,000.00
Net Margins: -79.83%
Pretax Margin: -79.83%
Return on Equity: -201.62%
Return on Assets: -58.60%

Debt

Debt-to-Equity Ratio: 2.15
Current Ratio: 4.23
Quick Ratio: 3.45

Sales & Book Value

Annual Sales: $58.45 million
Price / Sales: 2.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.77 per share
Price / Book: 6.69

Miscellaneous

Outstanding Shares: 24,650,000
Free Float: 23,245,000
Market Cap: $126.95 million
Optionable: Optionable
Beta: 0.95

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Antony Koblish (Age 58)
Co-founder, President, CEO & Director
Comp: $967.67k
Mr. Roberto E. Cuca J.D. (Age 56)
CFO & COO
Comp: $643.37k
Mr. Paul Talmo
Chief Technology Officer
Ms. Megan Smeykal (Age 48)
VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer
Mr. D. Taylor Ocasio
General Counsel & Corporate Secretary
Ms. Jennifer Lou Armstrong (Age 54)
Senior Vice President of Human Resources
Mr. Gregory A. Firestone
Chief Business Officer
Mr. Michael Leonard
Senior Vice President of Technical Operations
Mr. Peter C. Murphy (Age 51)
Chief Commercial Officer
Comp: $542.34k
Louisa Smith
Investor Relations Contact Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TELA Stock Analysis - Frequently Asked Questions

Should I buy or sell TELA Bio stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TELA Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TELA shares.
View TELA analyst ratings or view top-rated stocks.
What is TELA Bio's stock price target for 2024?: 3 equities research analysts have issued 12 month price objectives for TELA Bio's stock. Their TELA share price targets range from $12.00 to $15.00. On average, they predict the company's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 165.4% from the stock's current price.
View analysts price targets for TELA or view top-rated stocks among Wall Street analysts.
How have TELA shares performed in 2024?: TELA Bio's stock was trading at $6.62 at the start of the year. Since then, TELA stock has decreased by 22.2% and is now trading at $5.15.
View the best growth stocks for 2024 here.
When is TELA Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TELA earnings forecast.
How were TELA Bio's earnings last quarter?: TELA Bio, Inc. (NASDAQ:TELA) released its earnings results on Thursday, March, 21st. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.09. The business had revenue of $17 million for the quarter, compared to analyst estimates of $16.65 million. TELA Bio had a negative trailing twelve-month return on equity of 201.62% and a negative net margin of 79.83%.
What ETF holds TELA Bio's stock?: Jacob Forward ETF holds 23,758 shares of TELA stock, representing 3.71% of its portfolio.

What guidance has TELA Bio issued on next quarter's earnings?: TELA Bio updated its FY 2024 earnings guidance on Thursday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $74.0 million-$76.0 million, compared to the consensus revenue estimate of $75.2 million.
What other stocks do shareholders of TELA Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TELA Bio investors own include Micron Technology (MU), Intel (INTC), Pfizer (PFE), CrowdStrike (CRWD), Walt Disney (DIS), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Alteryx (AYX) and Cisco Systems (CSCO).
When did TELA Bio IPO?: TELA Bio (TELA) raised $60 million in an IPO on Friday, November 8th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
How do I buy shares of TELA Bio?: Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TELA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial